clinical trials for tirzepatide New trial: Zepbound (tirzepatide) helped adults lose an average of 20.2% of their body weight—around 50 lbs—over 72 weeks, outperforming Wegovy's 13.7% (~33 lbs). Credit to: https://www.healthline.com/health-news/zepbound-wegovy-weight-loss FDA Approves Tirzepatide, A Potential

Last reviewed: June 15, 2026 Last updated: June 15, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations

Fatigue: Some researchers report temporary fatigue during the first few days, which may reflect the body increased healing activity diverting energy resources toward tissue repair

Interestingly, some patients experience improved sleep quality as a result of weight loss and better glycemic control on tirzepatide

TK Tariq Khalil

If successful, the amount of an Ozempic lawsuit payout will depend on the specific facts of the case and how severe the injuries are

Those of us whose tax dollars supported his curiosity are the beneficiaries